Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2040225 | 0.87 | MAPT (0.39) | MAPTPOLBKDM4EGAAKDM5B | |
| SCHEMBL470433 | 0.83 | KDM4E (0.41) | MAPTPOLBKDM4EGAAKDM5B | |
| SCHEMBL470423 | 0.81 | MAPT (0.41) | MAPTPOLBKDM4EGAAKDM5B | |
| SCHEMBL2054043 | 0.80 | AURKA (0.47) | MAPTPOLBKDM4EGAAKDM5B | |
| SCHEMBL470323 | 0.78 | MAPT (0.52) | MAPTPOLBKDM4EGAAALDH1A1 | |
| SCHEMBL2043538 | 0.74 | KDM4E (0.42) | MAPTPOLBKDM4EGAAKDM5B | |
| SCHEMBL2042378 | 0.73 | ALDH1A1 (0.52) | MAPTPOLBKDM4EGAAALDH1A1 | |
| SCHEMBL457202 | 0.73 | DPP4 (0.52) | MAPTPOLBKDM4ETSHRALDH1A1 | |
| SCHEMBL15475992 | 0.73 | NPC1 (0.53) | MAPTPOLBKDM4EGAAALDH1A1 | |
| SCHEMBL14698589 | 0.72 | MAPT (0.49) | MAPTPOLBKDM4ETSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516008-B1 | NOVEL ANTIVIRAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-04-16 | — | — | EP | disclosed |
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-12-13 | — | — | US | disclosed |
| EP-2516008-A1 | NOVEL ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076765-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MAPT 3089/4885POLB 134/4885KDM4E 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.